International Coalition of Medicines Regulatory Authorities (ICMRA)

ICMRA has pledged its collective support in countering global COVID-19 pandemic

Click here ↗ (opens in new tab) for more information on ICMRA's collective efforts to expedite and streamline the development, authorisation and availability of COVID-19 treatments and vaccines worldwide.

Highlights:

• ICMRA and World Health Organisation (WHO) joint statement for healthcare professionals: How COVID-19 vaccines are regulated for safety and effectiveness ↗ (opens in new tab)

• ICMRA statement on Global Pharmaceutical Quality Knowledge Management: Enhancing Regulatory Reliance and Agility ↗ (opens in new tab)

• ICMRA statement on COVID-19: International regulators pledge collective support to combat COVID-19 ↗ (opens in new tab)

• ICMRA statement on clinical trials: International regulators provide guidance on prioritisation of COVID-19 clinical trials ↗ (opens in new tab)

About the ICMRA

The International Coalition of Medicines Regulatory Authorities (ICMRA) is a voluntary, executive-level, strategic coordinating, advocacy and leadership entity of regulatory authorities that work together to

• address current and emerging human medicine regulatory and safety challenges globally, strategically and in an on- going, transparent, authoritative and institutional manner

• provide direction for areas and activities common to many regulatory authorities' missions

• identify areas for potential synergies

• wherever possible, leverage existing initiatives/enablers and resources

The ICMRA will provide a global architecture to support enhanced communication, information sharing, crisis response and address regulatory science issues.

Refer to the ICMRA website ↗ (opens in new tab) for more news and activities.